InMed Pharmaceuticals financials
$1.38+1.10%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY26 Jun 30 | FY25 Jun 30 | FY24 Jun 30 | FY23 Jun 30 | FY22 Jun 30 | FY21 Jun 30 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $4.6M | $4.1M | $1.1M | $0.00 |
| Gross profit | $0.00 | $0.00 | $1.1M | $1.4M | $543.5K | $0.00 |
| Gross margin | — | — | 23.9% | 33.9% | 49.9% | — |
| Operating income | -$9.9M | -$8.4M | -$8.2M | -$8.4M | -$17.3M | -$9.9M |
| Net income | -$13.0M | -$8.2M | -$7.7M | -$7.9M | -$18.6M | -$10.2M |
| Net margin | — | — | −166.9% | −192.2% | −1707.3% | — |
| Diluted EPS | $-3.12 | $-8.36 | $-20.14 | $-65.00 | $-663.40 | $-759.20 |
| EBITDA | -$9.7M | -$8.2M | -$8.0M | -$8.2M | -$13.3M | -$9.8M |
| Operating cash flow | -$8.6M | -$8.1M | -$7.0M | -$7.3M | -$15.6M | -$9.7M |
| Free cash flow | -$8.6M | -$8.1M | -$7.0M | -$7.4M | -$15.6M | -$9.7M |
| Diluted shares | 4.2M | 1.0M | 0.4M | 0.1M | 0.0M | 0.0M |
Balance sheet
| Period end | Jun 30 | Jun 30 | Jun 30 | Jun 30 | Jun 30 | Jun 30 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $2.2M | $10.7M | $6.6M | $8.9M | $6.2M | $7.4M |
| Short-term investments | $39.7K | $43.4K | $43.1K | $44.4K | $44.8K | $46.5K |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $3.0M | $15.6M | $11.8M | $14.1M | $12.8M | $9.8M |
| Total liabilities | $2.0M | $2.1M | $2.6M | $2.0M | $3.7M | $2.4M |
| Shareholders' equity | $1.1M | $13.4M | $9.2M | $12.1M | $9.1M | $7.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology